Beam Therapeutics Inc
BEAM16.860USD
+0.220+1.32%
Close 08/27, 16:00（ET）Quotes delayed by 15 min
1.70BMarket Cap
LossP/E TTM
More Details of Beam Therapeutics Inc Company
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Company Info
Ticker SymbolBEAM
Company nameBeam Therapeutics Inc
IPO dateFeb 06, 2020
CEOMr. John M. Evans
Number of employees483
Security typeOrdinary Share
Fiscal year-endFeb 06
Address238 Main Street
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02142
Phone18573278775
Websitehttps://beamtx.com/
Ticker SymbolBEAM
IPO dateFeb 06, 2020
CEOMr. John M. Evans
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-6.45%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-97.47%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
--
--
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Independent Director
Independent Director
--
--
Ms. Christi Shaw
Ms. Christi Shaw
Independent Director
Independent Director
--
--
Dr. Mark C. Fishman, M.D.
Dr. Mark C. Fishman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Graham K. Cooper
Mr. Graham K. Cooper
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-6.45%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-97.47%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
--
--
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
7.47M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.38%
ARK Investment Management LLC
10.29%
Farallon Capital Management, L.L.C.
9.90%
The Vanguard Group, Inc.
9.58%
BlackRock Institutional Trust Company, N.A.
6.64%
Other
51.21%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.38%
ARK Investment Management LLC
10.29%
Farallon Capital Management, L.L.C.
9.90%
The Vanguard Group, Inc.
9.58%
BlackRock Institutional Trust Company, N.A.
6.64%
Other
51.21%
Shareholder Types
Shareholders
Proportion
Investment Advisor
55.18%
Hedge Fund
20.88%
Investment Advisor/Hedge Fund
19.51%
Venture Capital
4.81%
Research Firm
3.80%
Individual Investor
1.27%
Bank and Trust
0.67%
Pension Fund
0.28%
Family Office
0.06%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
537
101.17M
100.03%
+11.84M
2025Q1
562
100.13M
99.59%
+12.37M
2024Q4
542
80.18M
95.83%
-6.23M
2024Q3
539
78.60M
95.42%
-7.95M
2024Q2
538
78.23M
95.09%
-5.21M
2024Q1
550
76.09M
93.23%
-4.97M
2023Q4
549
75.48M
92.79%
-3.23M
2023Q3
554
74.84M
95.14%
-3.35M
2023Q2
566
72.06M
94.81%
-2.24M
2023Q1
583
68.81M
92.54%
-724.80K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
7.60M
7.56%
+4.49M
+144.60%
Mar 31, 2025
ARK Investment Management LLC
8.48M
8.43%
+1.41M
+19.98%
Mar 31, 2025
Farallon Capital Management, L.L.C.
9.93M
9.87%
+1.69M
+20.50%
Mar 31, 2025
The Vanguard Group, Inc.
8.85M
8.8%
+1.24M
+16.36%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.76M
6.72%
+838.01K
+14.15%
Mar 31, 2025
Nikko Asset Management Co., Ltd.
4.27M
4.24%
+309.26K
+7.81%
Mar 31, 2025
ARCH Venture Partners
4.54M
4.51%
--
--
Mar 31, 2025
State Street Global Advisors (US)
3.44M
3.42%
+362.74K
+11.79%
Mar 31, 2025
Bellevue Asset Management AG
2.40M
2.38%
+877.81K
+57.82%
Mar 31, 2025
Kynam Capital Management LP
2.52M
2.5%
+762.01K
+43.39%
Mar 31, 2025
View more
Related ETFs
Updated: Wed, Aug 6
Updated: Wed, Aug 6
Name
Proportion
ARK Genomic Revolution ETF
3.21%
Global X Genomics & Biotechnology ETF
2.09%
WisdomTree BioRevolution Fund
1.74%
ARK Innovation ETF
1.58%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
Franklin Genomic Advancements ETF
0.79%
SPDR S&P Biotech ETF
0.61%
Direxion Daily S&P Biotech Bull 3X Shares
0.39%
iShares Health Innovation Active ETF
0.2%
Invesco Nasdaq Biotechnology ETF
0.19%
View more
ARK Genomic Revolution ETF
Proportion3.21%
Global X Genomics & Biotechnology ETF
Proportion2.09%
WisdomTree BioRevolution Fund
Proportion1.74%
ARK Innovation ETF
Proportion1.58%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.88%
Franklin Genomic Advancements ETF
Proportion0.79%
SPDR S&P Biotech ETF
Proportion0.61%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.39%
iShares Health Innovation Active ETF
Proportion0.2%
Invesco Nasdaq Biotechnology ETF
Proportion0.19%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
